Merscope is the company's integrated platform for generating multiplexed error-robust fluorescence in situ hybridization (MERFISH) measurements. In March, the company announced that Merscope will become commercially available in the summer of 2021.

The series B financing was co-led by Novalis LifeSciences and current investor Northpond Ventures.

Vizgen launches integrated Merscope in situ imaging platform
Vizgen has launched its Merscope platform, a multiplexed, error-robust, single-cell in situ transcriptomic imaging technology.

Vizgen debuts accelerator lab in the U.S.
Life sciences company Vizgen has established an accelerator lab in the U.S. to advance pharmaceutical research and development.